Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics reported a significant increase in sales, with 7,233 nanochannel array flowcells sold in 2Q25, representing a 17% rise from the same quarter in the previous year. The company showcased strong growth in its consumables and software revenue streams, which increased by 16% year-over-year in 2Q25, leading to an overall 11% growth in combined revenue from consumables, software, and other services after adjustments. Furthermore, Bionano anticipates higher installation expectations for its OGM system in FY2025, projecting 20-25 installations, reflecting the company's expanding footprint in key markets, including the promising growth in Japan.

Bears say

Bionano Genomics faces several critical risks that contribute to a negative outlook on its stock, including lower-than-expected market uptake of its products and underutilization of installed systems, which may hinder revenue growth. Additionally, the company's potential inability to secure additional capital could restrict its operational capabilities, while the risk of dilution further complicates the financial landscape. The reliance on a conservative EV/Revenue multiple indicates an uncertain sales environment, reinforcing doubts about achieving projected financial performance in the near term.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.